GRI Bio (GRI) Enterprise Value (2020 - 2026)
GRI Bio (GRI) posted quarterly Enterprise Value of -$11.0 million for Q1 2026, down 236.73% year-over-year from $8.1 million in Q1 2025, and down 34.26% quarter-over-quarter from -$8.2 million in Q4 2025.
GRI Bio (GRI) Enterprise Value (2020 - 2026) Analysis & Trends
GRI Bio's Enterprise Value history runs 7 years deep, the most recent figure standing at -$11.0 million for Q1 2026.
- In Q1 2026, Enterprise Value fell 236.73% year-over-year to -$11.0 million; the TTM figure through Mar 2026 stood at -$11.0 million (down 236.73% YoY), while the FY2025 annual figure was -$8.2 million, down 63.66% from the prior year.
- Enterprise Value for Q1 2026 stood at -$11.0 million, down from -$8.2 million in the prior quarter.
- The five-year high for Enterprise Value was -$9000.0 in Q4 2022, with the low at -$11.0 million in Q1 2026.
- The 5-year median for Enterprise Value is -$4.8 million (2023), against an average of -$4.8 million.
- The sharpest annual moves came in 2022 and 2023: Enterprise Value surged 99.88% in 2022, then plunged 19988.89% in 2023.
- GRI Bio's Enterprise Value stood at -$9000.0 in 2022, then slumped by 19988.89% to -$1.8 million in 2023, then tumbled by 178.1% to -$5.0 million in 2024, then slumped by 63.66% to -$8.2 million in 2025, then slumped by 34.26% to -$11.0 million in 2026.
- Business Quant data shows GRI's Enterprise Value at -$11.0 million in Q1 2026, -$8.2 million in Q4 2025, and -$4.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | GRI Bio | 3.07 Mn | 3.07 Mn | - | -10.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11.05 Mn |
| Dec 31, 2025 | -8.23 Mn |
| Sep 30, 2025 | -4.06 Mn |
| Jun 30, 2025 | -5.12 Mn |
| Mar 31, 2025 | -3.28 Mn |
| Dec 31, 2024 | -5.03 Mn |
| Sep 30, 2024 | -4.75 Mn |
| Jun 30, 2024 | -6.35 Mn |
| Mar 31, 2024 | -4.09 Mn |
| Dec 31, 2023 | -1.81 Mn |
| Sep 30, 2023 | -3.49 Mn |
| Jun 30, 2023 | -4.80 Mn |
| Mar 31, 2023 | -1.67 Mn |
| Dec 31, 2022 | -9,000.00 |
| Sep 30, 2022 | -5.15 Mn |
| Jun 30, 2022 | -6.97 Mn |
| Mar 31, 2022 | -5.18 Mn |
| Dec 31, 2021 | -7.51 Mn |
| Sep 30, 2021 | -9.14 Mn |
| Jun 30, 2021 | -10.46 Mn |